<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616187</url>
  </required_header>
  <id_info>
    <org_study_id>1931/Si.270 am 8.5.03</org_study_id>
    <secondary_id>ATV-D-03-007G</secondary_id>
    <nct_id>NCT00616187</nct_id>
  </id_info>
  <brief_title>Atorvastatin in Relapsing-Remitting Multiple Sclerosis</brief_title>
  <official_title>Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II open-label baseline-to-treatment trial was designed to evaluate the safety,&#xD;
      tolerability and efficacy of orally administered atorvastatin in patients with&#xD;
      relapsing-remitting multiple sclerosis (RRMS). Patients with at least one&#xD;
      gadolinium-enhancing lesion (CEL) at screening by magnetic resonance imaging (MRI) were&#xD;
      eligible for the study. Patients are screened and enrolled in the outpatient clinic of the&#xD;
      Cecilie Vogt Clinic at the Charité - University Medicine Berlin. After a baseline period of 3&#xD;
      monthly MRI scans (months -2 to 0), patients followed a 9-month treatment period on 80 mg&#xD;
      atorvastatin daily. The primary endpoint is the number of CEL in treatment months 6 to 9&#xD;
      compared to baseline. Secondary endpoints include other MRI-based parameters and changes in&#xD;
      clinical scores and immune responses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of MRI contrast enhancing lesions</measure>
    <time_frame>treatment months 6 to 9 compared to baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>other MRI-based parameters (CEL volume, T2-lesion load, T1-hypointense lesion volume, whole brain magnetization transfer ratio, and apparent diffusion coefficient of normal appearing white matter)</measure>
    <time_frame>treatment months 6 to 9 compared to baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>interferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>untreated</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon beta treatment to add-on atorvastatin treatment</intervention_name>
    <description>IFN-β-1a 22 µg s.c. 3 times weekly or IFN-β-1b s.c. every other day (3 months baseline) and add on oral daily 80 mg atorvastatin (9 months add on treatment)</description>
    <arm_group_label>interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>untreated to atorvastatin treatment</intervention_name>
    <description>no treatment(3 months baseline)and oral daily 80 mg atorvastatin (9 months add on treatment)</description>
    <arm_group_label>untreated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 - 55 years old&#xD;
&#xD;
          -  MS diagnosis according McDonald criteria&#xD;
&#xD;
          -  Relapsing-remitting MS&#xD;
&#xD;
          -  EDSS 0 - 6&#xD;
&#xD;
          -  Disease activity as occurrence of CEL in brain MRI&#xD;
&#xD;
          -  IFN-beta therapy for at least 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary chronic progressive MS&#xD;
&#xD;
          -  Symptoms and signs of clinical disease conditions similar to MS&#xD;
&#xD;
          -  Conditions that can disturb MRI measurements&#xD;
&#xD;
          -  Clinically relevant GI diseases eg Colitis ulcerosa, Crohns disease, history of Ulcus&#xD;
             pepticum&#xD;
&#xD;
          -  Clinically relevant lung, heart, CNS, infectious disease&#xD;
&#xD;
          -  Clinically relevant liver, kidney or bone marrow abnormalities (as defined by specific&#xD;
             clinical chemistry values)&#xD;
&#xD;
          -  Allergies towards Gd-DTPA&#xD;
&#xD;
          -  Allergies towards constituents of the therapeutic agent&#xD;
&#xD;
          -  Recruitment to other clinical trials within 6 months prior to or during this study&#xD;
&#xD;
          -  Pretreatment with complete lymph irradiation, antibody therapy against lymphocyte&#xD;
             populations (eg. anti-CD4, Campath-1H), mitoxantrone, cyclophosphamide, cyclosporin A,&#xD;
             human antibodies, all immunomodulatory or immunosuppressive agents including&#xD;
             recombinant cytokines or other potential experimental MS therapies (6 months prior to&#xD;
             study start), glatiramer acetate, azathioprine, IVIg (6 months prior to study start)&#xD;
             pregnancy or lactation&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Inhibitors of Cytochrom P 450 3A (eg. cyclosporin, macrolide antibiotics, azole&#xD;
             antimycotics).&#xD;
&#xD;
          -  Medical or psychological conditions that could hamper with the patients capacity to&#xD;
             understand patient information, to give the informed consent, to adhere to the&#xD;
             protocol of the study and to be able to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frauke Zipp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cecilie Vogt Clinic for Neurology, Charite, Berlin</affiliation>
  </overall_official>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>February 5, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <name_title>Professor Frauke Zipp</name_title>
    <organization>Cecilie Vogt Clinic for Neurology, Charite University, Berlin, Germany</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

